Abciximab

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Abciximab is a chimeric Fab fragment of a chimeric antibody of mice and humans against glycoprotein IIb/IIIa receptors. Abciximab binds with high affinity to activated forms of the receptor, thereby reducing fibrinogen binding to the secretory function of platelets.
The binding of Abciximab to the receptors is irreversible.

IndicationThis section has been translated automatically.

Approval for the treatment of unstable angina pectoris and for coronary interventions

Dosage and method of useThis section has been translated automatically.

Initially 0.25 mg/kg body weight, then 0.125 ug/kg/min over 12 hours.
Dose adjustment for liver and kidney failure.

ContraindicationThis section has been translated automatically.

Severe renal insufficiency

PreparationsThis section has been translated automatically.

ReoPro®

LiteratureThis section has been translated automatically.

  1. HA Neumann (2014) The coagulation system. ABW-Scientific Publisher GmbH Berlin

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer